Please assess the completion status of the following clinical trial:

Trial Title: Celecoxib After Tonsillectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females age 3 to 11 years inclusive.~2. Scheduled to undergo tonsillectomy (with or without adenoidectomy).~3. Weight ≥10 kg.~4. Girls ≥ 11 years of age must have a negative urine/serum pregnancy test on the day of surgery and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study.~5. Parental/guardian permission (informed consent) and if appropriate, child assent.~Exclusion Criteria:~1. Prior adenotonsillar surgery.~2. Concomitant surgical procedure that adds more than mild additional pain. Note: ear tubes are always permissible.~3. Coagulation disorder, or any other hematologic disorder that affects clotting or results in anemia.~4. Moderate to severe asthma, defined as subjects who either (1) have daily symptoms requiring daily use of short-acting bronchodilators, or (2) had an exacerbation in the last 3 months requiring admission, emergency department (ED) visit, or systemic corticosteroid administration.~5. Any degree of aspirin-sensitive asthma, or any history of asthma exacerbation caused by NSAID use.~6. Severe obstructive sleep apnea, defined as an obstructive apnea-hypopnea index \>30 per hour and/or lowest oxygen saturation below 80%~7. Significant chronic pulmonary disease, defined as subjects requiring oxygen therapy, ventilator support, or positive pressure therapy.~8. Significant cardiac disease, defined as any one of the following: cardiovascular disease, structural cardiac anomalies, prior cardiac surgery, or requirement for cardiac anesthesia.~9. Severely obese (weight or body mass index \> 95th percentile for age) or underweight (weight \<5th percentile for age).~10. History of hepatic or renal disease, or condition that impairs hepatic or renal function.~11. Juvenile rheumatoid arthritis (JRA).~12. History of GI bleeding, or chronic GI condition that would increase risk of bleeding, ulceration, or perforation~13. Hypertension.~14. Craniofacial syndromes.~15. Syndrome or neurologic condition that would hinder accurate assessment of postoperative pain.~16. Inability to feed orally or take oral pain medication.~17. Chronic pain disorders, or otherwise requiring pain medication more than once weekly.~18. Laboratory abnormalities on the preoperative complete blood count (CBC):~    * Hemoglobin \< 9 gm/dL~   * Platelet count \< 100,000/mm3~19. Any investigational drug use within 30 days prior to enrollment.~20. Pregnant or lactating females.~21. Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.~22. Hypersensitivity or allergic reactions to celecoxib, aspirin, or other NSAIDs, including asthma flare ups~23. Allergy to sulfonamides or calcium carbonate.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Acetaminophen/Oxycodone + Celecoxib (Type: EXPERIMENTAL): Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take celecoxib orally (dose is 6mg/kg twice a day with a maximum dose of 300mg twice a day). The first dose of celecoxib will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
- Acetaminophen/Oxycodone + Placebo (Type: ACTIVE_COMPARATOR): Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take the placebo orally twice a day. The first dose of placebo will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).